In a 2018 guidance, FDA explained that it would consider a compounded drug to be essentially a copy of a commercially available drug if it has (i) the same API, (ii) the same or similar dosage, and (iii) the same route of administration, unless a prescriber determines that there is a change, made for an identified individual patient, which produces, for that patient, a significant difference from the commercially available drug product. The guidance also explains that, if a change is made for an identified patient, the prescriber should document the determination on the prescription, and the notations should be specific
GLP-1 receptors are distributed in multiple brain regions implicated in mood regulation, such as the hypothalamus, hippocampus, amygdala, and pancreas
It also tends to overlap with both obesity and type 2 diabetes both conditions for which people may take Ozempic
Oral options are now becoming more important, including oral semaglutide formulations and orforglipron, marketed as Foundayo
Drinking water, exercising, and increasing fiber intake can help alleviate symptoms